Edison Investment initiates coverage on Cereno Scientific
It’s come to our attention that Edison has initiated coverage of Cereno with a valuation of SEK 2.32bn and a price range of SEK 9.9/share. For further information, please contact: Henrik Westdahl, Director IR & Communications Email: henrik.westdahl@cerenoscientific.com Phone: +46 70-817 59 96 Sten R. Sörensen, CEO Email: sten.sorensen@cerenoscientific.com Phone: +46 73-374 03 74 About Cereno Scientific AB Cereno Scientific develops innovative treatments for common and rare cardiovascular disease. The lead drug candidate, CS1, is a HDAC (histone